Posted by Michael Wonder on 03 Jan 2024
Theratechnologies submits sBLA for Trogarzo intramuscular method of administration to FDA
2 January 2024 - Submission comes on the heels of the recent FDA approval of the Trogarzo intravenous push loading dose.
Theratechnologies today announced that the Company has filed a supplemental biologics license application for an intramuscular method of administration for the maintenance dose of Trogarzo (ibalizumab-uiyk) to the US FDA for review.
